PF-06651600

Code: PZ0316-25MG D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

PF-06651600 specifically targets the ATP (adenosine triphosphate)-binding domain of JAK3 (Janus kinase 3). Loss of function of JAK3 is associated with...


 En savoir plus

Votre prix
$403.86 25MG
DEMANDER

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

PF-06651600 specifically targets the ATP (adenosine triphosphate)-binding domain of JAK3 (Janus kinase 3). Loss of function of JAK3 is associated with severe combined immunodeficiency syndrome.

PF-06651600 is a potent and selective JAK3 inhibitor.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Packaging

5, 25 mg in glass bottle

assay≥98% (HPLC)
colorwhite to beige
formpowder
InChI keyQMPMPSGDPRHZCG-VZXYPILPSA-N
InChI1S/C15H19N5O.C3H4O4/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15;4-2(5)1-3(6)7/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19);1H2,(H,4,5)(H,6,7)/t10-,11+;/m0./s1
manufacturer/tradenamePfizer®
originatorPfizer
Quality Level100
SMILES stringC[C@@H]1N(C(C=C)=O)C[C@H](NC2=NC=NC3=C2C=CN3)CC1.OC(CC(O)=O)=O
solubilityH2O: 5 mg/mL, clear (warmed)
storage temp.room temp
Cas Number1792180-81-4
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN
GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.